{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T17:41:20Z","timestamp":1785865280815,"version":"3.56.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1016\/j.ajo.2011.01.059","type":"journal-article","created":{"date-parts":[[2011,6,19]],"date-time":"2011-06-19T17:05:18Z","timestamp":1308503118000},"page":"183-188.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Use of Infliximab in the Treatment of Peripheral Ulcerative Keratitis in Crohn Disease"],"prefix":"10.1016","volume":"152","author":[{"given":"Mary","family":"Pham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clement C.","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Badawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elmer Y.","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ajo.2011.01.059_bib1","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.survophthal.2003.08.004","article-title":"Inflammatory bowel disease and the eye","volume":"48","author":"Ghanchi","year":"2003","journal-title":"Surv Ophthalmol"},{"issue":"8","key":"10.1016\/j.ajo.2011.01.059_bib2","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1136\/bjo.58.8.732","article-title":"Ocular disorders in a series of 332 patients with Crohn's disease","volume":"58","author":"Hopkins","year":"1974","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2011.01.059_bib3","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1097\/01.ico.0000214206.29823.2d","article-title":"Corneal perforation due to severe peripheral ulcerative keratitis in Crohn disease","volume":"25","author":"Tan","year":"2006","journal-title":"Cornea"},{"issue":"12","key":"10.1016\/j.ajo.2011.01.059_bib4","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1136\/gut.34.12.1705","article-title":"Location of tumour necrosis factor \u03b1 by immunohistochemistry in chronic inflammatory bowel disease","volume":"34","author":"Murch","year":"1993","journal-title":"Gut"},{"issue":"9","key":"10.1016\/j.ajo.2011.01.059_bib5","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1136\/gut.33.9.1214","article-title":"Detection of mRNAs for macrophage products in inflammatory bowel disease by in situ hybridization","volume":"33","author":"Cappello","year":"1992","journal-title":"Gut"},{"issue":"8785","key":"10.1016\/j.ajo.2011.01.059_bib6","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0140-6736(92)90999-J","article-title":"Tumour necrosis factor alpha in stool as a marker of intestinal inflammation","volume":"339","author":"Braegger","year":"1992","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.ajo.2011.01.059_bib7","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor \u03b1 for Crohn's disease","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ajo.2011.01.059_bib8","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0016-5085(95)90277-5","article-title":"Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)","volume":"109","author":"van Dulleman","year":"1995","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.ajo.2011.01.059_bib9","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/S0161-6420(95)30963-3","article-title":"Therapy of nonnecrotizing anterior scleritis with subconjunctival corticosteroid injection","volume":"102","author":"Tu","year":"1995","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.ajo.2011.01.059_bib10","first-page":"1607","article-title":"Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice","volume":"149","author":"M\u00fcller-Ladner","year":"1996","journal-title":"Am J Pathol"},{"issue":"8","key":"10.1016\/j.ajo.2011.01.059_bib11","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1002\/1529-0131(200008)43:8<1710::AID-ANR6>3.0.CO;2-Y","article-title":"Cartilage degradation and invasion by rheumatoid synovial fibroblasts is inhibited by gene transfer of a cell surface-targeted plasmin inhibitor","volume":"43","author":"Van der Laan","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.ajo.2011.01.059_bib12","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1136\/bjo.83.12.1376","article-title":"Role of ocular matrix metalloproteinases in peripheral ulcerative keratitis","volume":"83","author":"Smith","year":"1999","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2011.01.059_bib13","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1136\/bjo.85.2.147","article-title":"Tear film MMP accumulation and corneal disease","volume":"85","author":"Smith","year":"2001","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2011.01.059_bib14","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/ICO.0b013e318181a84f","article-title":"Infliximab for the treatment of refractory progressive sterile peripheral ulcerative keratitis associated with late corneal perforation: 3-year follow-up","volume":"28","author":"Odorcic","year":"2009","journal-title":"Cornea"},{"issue":"6","key":"10.1016\/j.ajo.2011.01.059_bib15","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1097\/01.ico.0000154391.28254.1d","article-title":"Therapy of progressive rheumatoid arthritis-associated corneal ulceration with infliximab","volume":"24","author":"Thomas","year":"2005","journal-title":"Cornea"},{"issue":"6","key":"10.1016\/j.ajo.2011.01.059_bib16","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/01.rhu.0000249766.24780.95","article-title":"Rheumatoid arthritis-associated necrotizing scleritis and peripheral ulcerative keratitis treated successfully with infliximab","volume":"12","author":"Atchia","year":"2006","journal-title":"J Clin Rheumatol"},{"issue":"5","key":"10.1016\/j.ajo.2011.01.059_bib17","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1136\/bjo.2008.150961","article-title":"Infliximab for the treatment of refractory scleritis","volume":"94","author":"Doctor","year":"2010","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2011.01.059_bib18","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/03009740510026698","article-title":"Infliximab in the treatment of extra-intestinal manifestations of Crohn's disease","volume":"34","author":"Rispo","year":"2005","journal-title":"Scand J Rheumatol"},{"issue":"7","key":"10.1016\/j.ajo.2011.01.059_bib19","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1001\/archopht.125.7.895","article-title":"Infliximab therapy for the treatment of refractory ocular inflammatory disease","volume":"125","author":"Sobrin","year":"2007","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2011.01.059_bib20","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0161-6420(03)00721-8","article-title":"Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis","volume":"111","author":"Murphy","year":"2004","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.ajo.2011.01.059_bib21","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1111\/j.1572-0241.2008.01982_12.x","article-title":"Treatment of recurrent Crohn's uveitis with infliximab","volume":"103","author":"Ally","year":"2008","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"10.1016\/j.ajo.2011.01.059_bib22","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/j.ophtha.2006.04.038","article-title":"Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation","volume":"113","author":"Galor","year":"2006","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ajo.2011.01.059_bib23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5414\/CPP43007","article-title":"Infliximab in chronic ocular inflammation","volume":"43","author":"Baughman","year":"2005","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.ajo.2011.01.059_bib24","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/archopht.123.7.903","article-title":"A prospective trial of infliximab therapy for refractory uveitis: Preliminary safety and efficacy outcomes","volume":"123","author":"Suhler","year":"2005","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2011.01.059_bib25","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1572-0241.2002.05514.x","article-title":"Treatment of acute uveitis associated with Crohn's disease and sacroileitis with infliximab","volume":"97","author":"Fries","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.ajo.2011.01.059_bib26","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1136\/gut.2006.103564","article-title":"Risks and benefits of biologic therapy for inflammatory bowel diseases","volume":"56","author":"D'Haens","year":"2007","journal-title":"Gut"},{"issue":"19","key":"10.1016\/j.ajo.2011.01.059_bib27","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.ajo.2011.01.059_bib28","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.3899\/jrheum.081042","article-title":"Preventing tuberculosis flare in patients with inflammatory rheumatic diseases receiving tumor necrosis factor-alpha inhibitors in India\u2014An audit report","volume":"36","author":"Malaviya","year":"2009","journal-title":"J Rheumatol"},{"issue":"7","key":"10.1016\/j.ajo.2011.01.059_bib29","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.3899\/jrheum.100058","article-title":"Tumor necrosis factor-alpha blocker induced tuberculosis","volume":"37","author":"Kharbanda","year":"2010","journal-title":"J Rheumatol"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939411001449?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939411001449?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T13:02:52Z","timestamp":1757595772000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939411001449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S0002939411001449"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2011.01.059","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of Infliximab in the Treatment of Peripheral Ulcerative Keratitis in Crohn Disease","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2011.01.059","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}